Clinician- and Patient-reported Endpoints in CNS Orphan Drug Clinical Trials: ISCTM Position Paper on Best Practices...

Area of Science:

• Neurology
• Clinical Pharmacology
• Biostatistics

Background:

• Rare diseases necessitate distinct drug development strategies due to small patient populations and heterogeneous presentations.
• Challenges in rare disease drug development include limited sample sizes and lack of validated, standardized clinical endpoints.
• Existing endpoints may not be disease-specific, validated, or widely adopted in clinical practice.

Purpose of the Study:

• To provide an overview of critical issues concerning clinical trial endpoints in rare disease drug development.
• To offer practical guidance and discussion on endpoint selection and application for rare neurological disorders.
• To support the International Society of CNS Clinical Trials Methodology (ISCTM) mission in advancing rare disease therapeutics.

Main Methods:

• Review of regulatory considerations for endpoint selection in rare diseases.
• Discussion on identifying relevant measurement domains and quantifying clinical meaningfulness.
• Exploration of patient-reported outcomes, clinician-rated assessments, and cognitive assessment challenges.

Main Results:

• Comprehensive coverage of endpoint-related topics including regulatory aspects, outcome measures, and global considerations.
• Detailed examination of challenges in cognition assessment and translation for rare CNS diseases.
• Emphasis on training, standardization, calibration, and quality assurance for endpoint reliability.

Conclusions:

• The article provides essential guidance and resources for optimizing endpoint strategies in rare disease drug development.
• It encourages thoughtful consideration to improve the development of treatments for central nervous system (CNS) rare diseases.
• The ISCTM aims to streamline trials and foster advancements in orphan drug development for neurological conditions.